Innate Pharma: Breakthrough Therapy status for lacutamab

(CercleFinance.com) - Innate Pharma announces that its lacutamab has been granted Breakthrough Therapy status for the treatment of adults with relapsed or refractory Sézary syndrome who have received at least two prior systemic therapies, including mogamulizumab.


Breakthrough Therapy status, granted by the US FDA, is designed to accelerate the regulatory process for drugs intended to treat a serious disease and having shown encouraging early clinical results.

It was obtained on the basis of the results of the phase 2 TELLOMAK trial, which demonstrated encouraging efficacy and a favorable safety profile in heavily pre-treated, post-mogamulizumab patients with advanced Sézary syndrome.

Copyright (c) 2025 CercleFinance.com. All rights reserved.